Impressive data for 9MW2821 (Nectin4/MMAE ADC) & Toripalimab (n=40) RR =80% (EVP & DVP 73%/75% in phase 2). TRAEs >G3 neutrophil ⬇️ (8%), rash (5%), ALT⬆️ (5%). lrss skin tox? Also high responses in Nectin4 low. This will be in R3 very soon in china I suspect. #ASCO25

Deep, multi-omic analysis of adjuvant atezolizumab for ccRCC by Sumanta K. Pal, MD, FASCO and team building on prior KIM-1 studies. One take away is KIM-1 high, Teff high has longer DFS with atezo than placebo #ASCO25

Excellent presentation of EV +P response analysis by ⁦Shilpa Gupta⁩ #ASCO25 finds most CR durable and safety maintained despite median 13 cycles (up to 50!) EV due to dose modifications

Exceptionally clear, thoughtful discussion by ⁦Jacqueline Brown⁩ suggesting there may still be a role for SG in the future with appropriately designed trials including mandatory gcsf #ASCO25

Fantastic activity of first in class B7H3 ADC DB1311 for patients w metastatic castration resistant #prostatecancer - we had trial open w #KevinCourtney UTSW Simmons Cancer Center & had patients benefit! ASCO #ASCO25 OncoAlert

🗣️Prostate Rapid Oral Abstract #ASCO25 👉Abst5017: Dr #CapucineBaldini presenting #Pasritamig in mCRPC 🔑 KEY TAKE AWAYS - #Pasritamig well tolerated (<10% G1 CRS @ RP2D) with promising antitumor activity. - Proof of concept for #KLK2 as a target amenable to T-cell

Kudos Sumanta K. Pal, MD, FASCO on such a fantastic presentation and setting the stage for biomarker development in Kidney cancer! Neeraj Agarwal, MD, FASCO Brian Rini, MD Tom Powles Uromigos Toni Choueiri, MD Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky)

Thank you Vivek Narayan, of Penn Medicine - Abramson Cancer Center, for sharing the 5-year data with us on the HIF-2α inhibitor belzutifan in VHL disease–associated neoplasms. We can't believe it's been 4 years since its U.S. FDA approval. Check out hubs.li/Q03q4Lj10 for his insights ASCO #ASCO25

Beautiful lakeside run this morning - why have I never done this before?! #ASCO25 Chicago, you are one beautiful city!

Great poster session this morning with Nicolas Sayegh, MD highlighting work in #prostatecancer TMB & MSI-H w/ real world IO outcomes Foundation Medicine! Truly a star resident UTSW Simmons Cancer Center UTSW Internal Medicine co-mentored by me & Neeraj Agarwal, MD, FASCO. Look out for his fellowship apps this fall! #ASCO25

Fascinating deep science analyzing molecular underpinnings of sensitivity to 177Lu-PSMA-617 by Jacob Berchuk and Emory colleagues. Why wnt leads to resistance and how to target it? AR activity associated with a/ less response - counterintuitive #ASCO25

So great to see friends and colleagues at the poster session for GU including the esteemed and beloved Dr Small! Fantastic posters #ASCO25

Impactful work coming from VA data - here, earlier start of docetaxel (<4 months) better than >4 mo. Did inadequate response drive some of the later dosing? Excited to be collab w/ Dr Schoen thru ProfoundVET to improve #prostatecancer care #ASCO25 ⁦Jasnoor Malhotra⁩

Proud of my productive team of #GUOncology Ospedale San Raffaele Università Vita-Salute San Raffaele occupying the GU Poster Session ASCO #ASCO25 #PURE01 #SURE01 #NureCombo Conquer Cancer, the ASCO Foundation Brigida Maiorano Valentina Tateo Antonio Cigliola Chiara Mercinelli Key takeaways: - SURE01: Luminal subtype & Top1 expression linked

Tanya Dorff Jasnoor Malhotra Also love the SLU Medicine and Genitourinary Cancer Research Team @CityofHope connection including Sumanta K. Pal, MD, FASCO

Finally had a chance to listen to the discussion EVERYONE in the GU community is talking about via ASCO Virtual Meeting. One of the most thoughtful & eloquent discussions I have ever seen by Jacqueline T. Brown, MD Winship Cancer Institute of Emory University, summarizing excellent presentations from Michiel van der Heijden

Proud of my mentor Michael Ong presenting impt international #IRONMAN data: 🚹 mCSPC w/ ADT + ARPI 🌀PSA of >= 0.2 at 6-12mo = worse px (mOS 30mo) ➡️consider #TRIPLESWITCH intensification trial now open 🌀PSA<0.2 at 6-12mo = good px ➡️ consider #DEESCALATE trial #ASCO25

🗣️Prostate Oral Abstract #ASCO25 👉Abst5007: Dr Rana McKay, MD, FASCO presenting #Radium +/- #Olaparib in mCRPC w/ bone mets on #COMRADE n = 120 mCRPC w >2 bone mets Any line of prior therapy (96% ARPI, 53% Docetaxel) BPA required unless contra (90% use) 💊Arm A: #Radium + #Olaparib

A novel west-African germline founder mutation in HOXB13 (p.X285Kext) increases risk of high-grade prostate cancer but also enhances sensitivity to hormonal therapy. Congrats to PCF-funded Mayuko Kanayama 👏 Neeraj Agarwal, MD, FASCO Prostate Cancer Foundation UroToday.com Ed Esplin, MD, PhD nature.com/articles/s4139…

Thanks to Sumanta K. Pal, MD, FASCO for hosting. And thanks to @Waltstadler5 for his no nonsense insights. I've been learning from him for many years. It's a pleasure to push the cutting edge of cancer care with colleagues like this.